Bristol-Myers Squibb Co [NYSE: BMY] price surged by 1.62 percent to reach at $0.97.
The one-year BMY stock forecast points to a potential downside of -0.51. The average equity rating for BMY stock is currently 2.58, trading closer to a bullish pattern in the stock market.
Guru’s Opinion on Bristol-Myers Squibb Co [BMY]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BMY shares is $60.68 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BMY stock is a recommendation set at 2.58. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Jefferies have made an estimate for Bristol-Myers Squibb Co shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 16, 2024. While these analysts kept the previous recommendation, BofA Securities raised their target price to Neutral. The new note on the price target was released on December 10, 2024, representing the official price target for Bristol-Myers Squibb Co stock.
The Average True Range (ATR) for Bristol-Myers Squibb Co is set at 1.55, with the Price to Sales ratio for BMY stock in the period of the last 12 months amounting to 2.57. The Price to Book ratio for the last quarter was 7.58, with the Price to Cash per share for the same quarter was set at 5.34. Price to Free Cash Flow for BMY in the course of the last twelve months was 8.90 with Quick ratio for the last quarter at 1.15.
BMY Stock Performance Analysis:
Bristol-Myers Squibb Co [BMY] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -0.10. With this latest performance, BMY shares gained by 2.30% in over the last four-week period, additionally plugging by 21.69% over the last 6 months – not to mention a rise of 14.54% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BMY stock in for the last two-week period is set at 57.32, with the RSI for the last a single of trading hit 59.24, and the three-weeks RSI is set at 56.33 for Bristol-Myers Squibb Co [BMY]. The present Moving Average for the last 50 days of trading for this stock 58.68, while it was recorded at 59.66 for the last single week of trading, and 52.88 for the last 200 days.
Insight into Bristol-Myers Squibb Co Fundamentals:
Bristol-Myers Squibb Co’s liquidity data is similarly interesting compelling, with a Quick Ratio of 1.15 and a Current Ratio set at 1.25.
BMY Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BMY. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for Bristol-Myers Squibb Co go to 73.72%.
Bristol-Myers Squibb Co [BMY] Institutonal Ownership Details
There are presently around $80.66%, or 80.72%% of BMY stock, in the hands of institutional investors. The top three institutional holders of BMY stocks are: VANGUARD GROUP INC with ownership of 186.57 million shares, which is approximately 9.2225%. BLACKROCK INC., holding 158.66 million shares of the stock with an approximate value of $$6.59 billion in BMY stocks shares; and BLACKROCK INC., currently with $$3.8 billion in BMY stock with ownership which is approximately 4.5114%.
